2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-11024
    ADP receptor-IN-1 1015435-62-7 98%
    ADP receptor-IN-1 (compound 21) is a platelet ADP receptor inhibitor. ADP receptor-IN-1 shows both IC50 values <10 μM at a platelet ADP receptor binding assay and aggregation using a platelet-rich plasma assay.
    ADP receptor-IN-1
  • HY-13769
    TPT-260 769856-81-7 98%
    TPT-260 (TPU260), a thiophene thiourea derivative, is a retromer complex stabilizer against thermal denaturation (Kd = ~5 µM). TPT-260 increases the levels of retromer proteins, shifts amyloid-precursor protein (APP) away from the endosome, and decreases the pathogenic processing of APP. TPT-260 inhibits TLR4 upregulation, IKKβ phosphorylation, NF-κB p65 nuclear translocation, and NLRP3 inflammasome formation. TPT-260 improves retromer-mediated cargo trafficking, reduces brain infarct area, and decreases amyloid plaque deposition. TPT-260 exhibits minimal cytotoxicity to primary microglia at tested concentrations. TPT-260 can be used for the research of inflammatory bowel disease, ischemic stroke and Alzheimer's disease.
    TPT-260
  • HY-14257
    BMS-191095 hydrochloride 166095-95-0 98%
    BMS-191095 hydrochloride is a mitochondrial KATP channel opener. BMS-191095 hydrochloride can protect the myocardium without causing vasodilation or affecting electrophysiology, by prolonging the contraction time during ischemia, improving contractile function after reperfusion, and reducing lactate dehydrogenase (LDHM) release, thereby exerting its cardioprotective effects.
    BMS-191095 hydrochloride
  • HY-15406
    BNC105P 945771-96-0 98%
    BNC105P is a phosphate prodrug of BNC105 (HY-16114), that exhibits activity as a vascular disrupting agent (VDA) and an antitumor agent through conversion to active BNC105.
    BNC105P
  • HY-15692
    PHD2-IN-3 1000025-14-8 98%
    PHD2-IN-3 (compound 2) is a PHD2 inhibitor. PHD2-IN-3 can be used for study of anemia.
    PHD2-IN-3
  • HY-17447
    Tranylcypromine 155-09-9 98%
    Tranylcypromine (SKF 385) is a potent monoamine oxidase (MAO) inhibitor.
    Tranylcypromine
  • HY-18211
    CGS 35601 849066-09-7 98%
    CGS 35601 is the inhibitor for endothelin-converting enzyme-1 (ECE-1), neutral endopeptidase 24.11 (NEP), and angiotensin-converting enzyme (ACE), with IC50s of 55, 2, and 22 nM, respectively. CGS 35601 suppresses the big endothelin-1 (big ET-1)- and angiotensin I-induced pressor response, and enhances circulation of atrial natriuretic peptide (ANP), regulates the cardiovascular function in SD rats.
    CGS 35601
  • HY-18347
    Conivaptan 210101-16-9 98%
    Conivaptan (YM 087 free base) is antagonist for vasopressin V1A receptor and vasopressin V2 receptor. Conivaptan ameliorates congestive heart failure, improves cardiac systolic function.
    Conivaptan
  • HY-19053
    NP-252 132031-81-3 98%
    NP-252 is a calcium channel antagonist with an 20% effective dose (ED20) of 2.55 mg/kg in spontaneously hypertensive rats.
    NP-252
  • HY-19062
    SM-6586 103898-38-0 98%
    SM-6586 is a calcium channel antagonist and inhibitor of Na+/H+ and Na+/Ca2+ exchange transport, potentially for the treatment of cerebrovasular diseases and hypertension.
    SM-6586
  • HY-19063
    SCH-34826 105262-04-2 98%
    SCH-34826 is an orally active neutral metalloendopeptidase (NEP) inhibitor that inhibits NEP and reduces the degradation of ANF, thereby enhancing its antihypertensive and diuretic effects. SCH-34826 can be used in the research of cardiovascular and renal diseases.
    SCH-34826
  • HY-19097
    Ro-24-4736 125030-71-9 98%
    Ro 24-4736 is a potent, selective, p.o.-active platelet-activating factor (PAF) antagonist with a long duration of action. Ro-24-4736 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Ro-24-4736
  • HY-19099
    Minopafant 128420-61-1 98%
    Minopafant (E 5880) is a PAF receptor antagonist. Minopafant can be used in studies of cerebral vasospasm following subarachnoid hemorrhage.
    Minopafant
  • HY-19115
    YM-430 153192-22-4 98%
    YM-430 is an oral active calcium entry-blocking and beta-adrenoceptor-blocking agent. YM-430 inhibits Amifampridine (HY-14946)-induced rhythmic contractions with an IC50 value of 59.2 nM and inhibits arginine vasopressin-induced ST-segment depression with an IC50 value of 36.6 mg/kg. YM-430 can be used for study of angina pectoris.
    YM-430
  • HY-19121
    TCV-309 131311-25-6 98%
    TCV-309 is an antagonist for platelet activating factor (PAF). TCV-309 improves the left ventricular function during ischemia-reperfusion (77.6% recover at 1 μM), protects the cardiac function.
    TCV-309
  • HY-19163
    SC-52012 145643-15-8 98%
    HY-19163 is an orally active fibrinogen receptor antagonist, with antiplatelet activities.
    SC-52012
  • HY-19191
    L-159282 157263-00-8 98%
    L-159282 is a highly potent, orally active, nonpeptide angiotensin II receptor antagonist, with anti-hypertensive activity.
    L-159282
  • HY-19210
    SB-209670 157659-79-5 98%
    SB-209670 is an extremely potent and highly specific non-peptide, subnanomolar endothelin (ET) receptor antagonist. SB 209670 selectively inhibits binding of 125I-labeled ET-1 to cloned human ET receptor subtypes ETA and ETB (Ki=0.2 and 18 nM, respectively). SB 209670 produces a dose-dependent reduction in blood pressure in hypertensive rats, protects from ischemia-induced neuronal degeneration in a gerbil stroke model, and attenuates neointima formation following rat carotid artery balloon angioplasty.
    SB-209670
  • HY-19214
    Elisartan 149968-26-3 98%
    Elisartan is an orally active non-peptide pro-agent of angiotensin II AT1 receptor antagonist HN-12206, and shows anti-hypertension activities.
    Elisartan
  • HY-19216
    KR-30450 172489-10-0 98%
    KR-30450 (SKP 450) is a potent K+ATP opener, and a potassium channel activator. KR-30450 exerts more potent cardioprotective effects than Lemakalim (HY-14255). KR-30450 significantly improves reperfusion cardiac function. KR-30450 significantly attenuates reperfusion contracture and lactate dehydrogenase release.
    KR-30450
Cat. No. Product Name / Synonyms Application Reactivity